Pharmaceutical Industry — Economic Framework
Economic Framework
India's pharmaceutical industry is the world's largest supplier of generic drugs, earning the title 'pharmacy of the world' by supplying 50% of global vaccine demand and 40% of US generic drug requirements.
The domestic market is valued at 25.4 billion in FY 2022-23. The industry operates under a complex regulatory framework including CDSCO for drug approvals, NPPA for price control under DPCO 2013, and Patents Act 2005 for intellectual property.
Key policy milestones include the Patents Act 1970 (enabling generic drug development through process patents), liberalization in 1991, and TRIPS compliance through Patents Act 2005. The sector employs 4.
7 million people and contributes significantly to India's export earnings. Major companies include Sun Pharma, Dr. Reddy's, Cipla, and Aurobindo Pharma. Challenges include limited R&D investment (6-8% vs global 15-20%), quality concerns, and dependence on Chinese APIs (68% of imports).
Government support includes PLI scheme (₹15,000 crores), bulk drug parks, and Atmanirbhar Bharat initiatives. COVID-19 highlighted both the sector's global importance through vaccine diplomacy and vulnerabilities in API supply chains.
The industry's future growth depends on addressing R&D gaps, quality improvements, and reducing import dependence while maintaining cost competitiveness in global markets.
Often confused with
Side-by-side differences the UPSC paper likes to test.
| Aspect | Pharmaceutical Industry | Healthcare Financing Mechanisms |
|---|---|---|
| Primary Focus | Manufacturing and supply of pharmaceutical products | Funding mechanisms for healthcare services and insurance |
| Regulatory Body | CDSCO, NPPA for pricing and quality control | IRDAI, Ministry of Health for insurance regulation |
| Market Structure | Mix of generic and branded drugs, export-oriented | Insurance-based financing, government schemes |
| Price Mechanism | DPCO-based price controls for essential medicines | Premium-based insurance models, government funding |
| Global Integration | Major exporter, 'pharmacy of the world' status | Limited international integration, domestic focus |
While pharmaceutical industry focuses on manufacturing and supplying medicines with strong export orientation, healthcare financing mechanisms concentrate on funding healthcare access through insurance and government schemes.
Both sectors complement each other in ensuring healthcare access - pharmaceuticals through affordable drug supply and financing through payment mechanisms. The pharmaceutical sector's price controls under DPCO directly impact healthcare financing by reducing medicine costs, while robust financing mechanisms create larger markets for pharmaceutical products.
Why it is tested: Questions often test understanding of how drug pricing policies interact with healthcare financing, the role of both sectors in achieving universal health coverage, and policy coordination between manufacturing and financing aspects of healthcare delivery.